W
Wanchi Fung
Publications - 6
Citations - 88
Wanchi Fung is an academic researcher. The author has contributed to research in topics: Prodrug & Antibody. The author has an hindex of 4, co-authored 6 publications receiving 66 citations.
Papers
More filters
Journal ArticleDOI
The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function
Christy M. Hebner,Bin Han,Katherine M. Brendza,Michelle Nash,Maisoun Sulfab,Yang Tian,Magdeleine Hung,Wanchi Fung,Vivian Randall W,Trenkle James D,James G. Taylor,Kyla Bjornson,Steven S. Bondy,Xiaohong Liu,John O. Link,Johan Neyts,Roman Sakowicz,Weidong Zhong,Hengli Tang,Uli Schmitz +19 more
TL;DR: It is demonstrated that upon metabolic activation TGV is a specific, covalent inhibitor of the HCV NS5B polymerase and is mechanistically distinct from other classes of the non-nucleoside inhibitors (NNI) of the viral polymerase.
Journal ArticleDOI
Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases
Peter A. Blomgren,Jayaraman Chandrasekhar,Julie Di Paolo,Wanchi Fung,Guoju Geng,Carmen Ip,Randall Mark Jones,Kropf Jeffrey E,Eric B. Lansdon,Seung H. Lee,Jennifer R. Lo,Scott A. Mitchell,Bernard P. Murray,Chris Pohlmeyer,Aaron C. Schmitt,Kimberly Suekawa-Pirrone,Sarah Wise,Jin-Ming Xiong,Jianjun Xu,Helen Yu,Zhongdong Zhao,Kevin S. Currie +21 more
TL;DR: The discovery of a second-generation SYK inhibitor, GS-9876 (lanraplenib), which has human pharmacokinetic properties suitable for once-daily administration and is devoid of any interactions with PPI.
Journal ArticleDOI
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
David Sperandio,Vangelis Aktoudianakis,Kerim Babaoglu,Xiaowu Chen,Kristyna Elbel,Gregory Chin,Britton Kenneth Corkey,Du Jinfa,Bob Jiang,Kobayashi Tetsuya,Richard L. Mackman,Martinez Ruben,Hai Yang,Jeff Zablocki,Saritha Kusam,Kim Jordan,Heather Webb,Jamie Bates,Latesh Lad,Mish Michael R,Anita Niedziela-Majka,Sammy Metobo,Annapurna Sapre,Magdeleine Hung,Debi Jin,Wanchi Fung,Elaine Kan,Gene Eisenberg,Nate Larson,Zachary Newby,Eric B. Lansdon,Chin Tay,Richard M. Neve,Sophia L. Shevick,David G. Breckenridge +34 more
TL;DR: The optimized dimethylisoxazole aryl-benzimidazole inhibitor exhibited high potency towards BRD4 and related BET proteins in biochemical and cell-based assays and inhibited tumor growth in two proof-of-concept preclinical animal models.
Proceedings ArticleDOI
Abstract 5012: Targeting CD39 with a first-in-class inhibitory antibody prevents ATP processing and increases T-cell activation
Alana G. Lerner,Maria Kovalenko,Megan Welch,Tracy dela Cruz,Jeffrey P. Jones,Clifford G. Wong,Bradley N. Spatola,Meghan Eberhardt,Andrew D. Wong,Wanchi Fung,Leanna Lagpacan,Karolina Losenkova,Gennady G. Yegutkin,Vanessa B. Soros,John Corbin,Courtney Beers,Achim K. Moesta +16 more
TL;DR: TTX-030 is a selective and potent CD39 enzymatic inhibitor, capable of preventing adenosine-mediated immune suppression and increasing T-cell activation, and represents a unique therapeutic target aimed at modulating the immunosuppressive TME in cancer.
Journal Article
Mutations in adenosine deaminase-like (ADAL) protein confer resistance to the antiproliferative agents N6-cyclopropyl-PMEDAP and GS-9219.
Christian R. Frey,Graciela Andrei,Ivan Votruba,Carina E. Cannizzaro,Bin Han,Wanchi Fung,Magdeleine Hung,Xiaohong Liu,Romas Geleziunas,Pierre Fiten,Ghislain Opdenakker,Robert Snoeck,Tomas Cihlar +12 more
TL;DR: The ADAL protein plays an essential role in the intracellular activation of GS-9219 by catalyzing the deamination of cPrPMEDAP metabolite to PMEG.